Showing 2040 results
-
Ad hoc release /Novartis appoints experienced pharmaceuticals industry leader with strong marketing skills to drive oncology business further Novartis appoints ad interim leader for its Global Drug Development…
-
Ad hoc release /Novartis ernennt eine erfahrene Pharma-Führungskraft mit starken Marketingfähigkeiten, um das Onkologiegeschäft weiter zu entwickeln Novartis ernennt ad interim Leiter für die Global Drug…
-
Press release /Aktionäre genehmigen für 2015 die 19. Dividendenerhöhung in Folge auf CHF 2,70 pro Aktie (+4%) Dr. Jörg Reinhardt als Präsident des Novartis Verwaltungsrats ebenso wie alle weiteren Mitglieder des…
-
Statement /
-
Story /Most people have never heard of spinal muscular atrophy (SMA), a rare genetic disease that affects approximately 1 in 6,000 babies born worldwide each year. Innovative research may produce treatments for patients suffering from SMA and other rare diseases.
-
Story /Make smart decisions about your research projects.
-
Story /Zebrafish imaging sheds light on human neurological conditions.
-
Story /The race is on to find a new treatment before resistance to today’s drugs becomes widespread.
-
Featured News /
Leprosy is an ancient disease that currently infects more than 200 000 people each year. For more than three decades, Novartis and the Novartis Foundation has been working to reduce the incidence of leprosy, and the Novartis Foundation recently helped establish the Global Partnership for Zero Leprosy in an effort to eliminate the disease.
-
Featured News /
Individualized CAR‑T therapy uses a patient’s own immune system to fight certain types of cancers.